Clinical Trial: NCT03815643
Avelumab Program Rollover Study
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | EMD Serono Research & Development Institute, Inc. |
| Information Provided By: | EMD Serono |
| Last Update Posted: | 2026-09-22 |
Study Overview
Brief Summary
The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.
Official Title
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
Conditions
Solid Tumors
Intervention / Treatment
- Drug: Avelumab
Other Study ID Numbers
- MS100070_0176
- 2018-003711-21
- 2024-514274-46-00
- jRCT2080224625
- JapicCTI-194697
- 2018
Start Date (Actual)
2019-03-22
Primary Completion Date (Estimated)
2026-11-24
Study Completion Date (Estimated)
2026-11-24
Enrollment (Actual)
205
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | EMD Serono Research & Development Institute, Inc. |
| Information Provided By: | EMD Serono |
| Last Update Posted: | 2026-09-22 |
Study Overview
Brief Summary
The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.
Official Title
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
Conditions
Solid Tumors
Intervention / Treatment
- Drug: Avelumab
Other Study ID Numbers
- MS100070_0176
- 2018-003711-21
- 2024-514274-46-00
- jRCT2080224625
- JapicCTI-194697
- 2018
Start Date (Actual)
2019-03-22
Primary Completion Date (Estimated)
2026-11-24
Study Completion Date (Estimated)
2026-11-24
Enrollment (Actual)
205
Study Type
Interventional
Phase
Phase 3